Continuous Glucose Monitor with Siri Integration Improves Glycemic Control in Legally Blind Patients with Diabetes
Halis Kaan Aktürk, Janet K. Snell‐Bergeon, Viral N. Shah
Abstract
Continuous glucose monitoring (CGM) is safe and effective in improving glycemic control in insulin-treated patients with diabetes. However, the safety of CGM use in legally blind patients with diabetes is unknown. This is a retrospective study of seven legally blind patients with diabetes on intensive insulin therapy who were using Dexcom G6 with voice-enabled Apple's Siri feature. CGM metrics, hemoglobin A1c, and frequency of severe hypoglycemia were measured for 12 months. There was a significant reduction in A1c after 3, 6, and 12 months of Dexcom G6 with Apple Siri use ( P < 0.0001). Time-in-range increased at 12 months (50.9% ± 5.5% at 3 months vs. 56.8% ± 5.5% at 12 months, P = 0.029) without increase in time spent in hypoglycemia. There was a significant reduction in severe hypoglycemia requiring medical assistance for 12 months. Voice-enabled CGM use improved glycemic control and reduced severe hypoglycemia in legally blind patients with diabetes on intensive insulin therapy.